MLYS
Mineralys Therapeutics, Inc.- Healthcare
- Biotechnology
- $2.49B market cap
Forecast run · Sep 14, 2026Upside rank 1373 of 3,136
Model Signal
ForecastQ Daily Probabilities
38.0%
48.0%
23.5%
Analyst Consensus
Recommendation2.13/5 Buy
Last price$28.20
Price target$43.20
Implied move+53.2%
Analysts8
ForecastQ Portfolios
MLYS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.